See the DrugPatentWatch profile for Dinutuximab
What is dinutuximab?
Dinutuximab is a monoclonal antibody used to treat high-risk neuroblastoma. It is designed to target a tumor antigen called GD2 (a marker found on neuroblastoma cells). 1
How does dinutuximab work in neuroblastoma?
Dinutuximab binds to GD2 on neuroblastoma cells. By attaching to that target, it helps the immune system recognize and attack the cancer. 1
When is dinutuximab used?
Dinutuximab is used for high-risk neuroblastoma as part of treatment in appropriate clinical settings described by its approved uses. 1
What are common side effects or safety issues people ask about?
Patients and caregivers often ask about side effects because GD2-targeted therapies can cause problems related to nerve pain and inflammation. The most notable issue commonly discussed is pain during treatment. Other side effects depend on the regimen and patient factors and are covered in the therapy’s prescribing information. 1
How is dinutuximab given?
Dinutuximab is administered by intravenous infusion as directed in the approved treatment plan. 1
What monitoring or supportive care is typically involved?
Because treatment can be painful and can involve infusion-related effects, clinicians typically provide supportive medications and monitoring as outlined in the product information and treatment protocols. 1
Is dinutuximab the same as dinutuximab beta or dinutuximab-gxly?
“Dinutuximab” may be referenced alongside specific product names and formulations used in different regions. The exact name matters because it corresponds to a specific approved product and prescribing information. 1
Sources